This Week in Obstetrics & Gynecology — Sep 24, 2026

This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.

Welcome to This Week in Obstetrics and Gynecology. This week we're covering 10 notable papers spanning hormones and metabolic health across the lifespan, benign and oncologic gynaecologic surgery, and diagnosis and prediction in early pregnancy and obstetrics. Let's dive in.

We start with two papers about hormones and metabolic risk in women outside of pregnancy. In the BMJ, Berggreen and colleagues report a nationwide nested case-control study drawn from Danish registries covering women aged 50 to 69 between 2003 and 2021, with nearly ten thousand cases of venous thromboembolism, more than eighteen thousand ischaemic strokes, and close to twelve thousand myocardial infarctions, each matched by birth year to controls without thrombotic disease [1]. Among women never exposed to menopausal hormone therapy, the background rates were roughly 16 venous thromboembolisms, 20 strokes and 13 infarctions per ten thousand person years. Current use of oral oestrogen, alone or with a progestin, was associated with about a sixty percent higher rate of venous thromboembolism and more modest increases in stroke and myocardial infarction. The authors put those in absolute terms that are easier to carry into a consultation: roughly one extra clot for every thousand women treated for a year, one extra stroke for every sixteen hundred, and one extra infarction for every few thousand. Risk climbed with dose and duration, with oral oestradiol above one milligram a day used for more than five years associated with roughly eighty percent higher rates of both stroke and infarction. Transdermal therapy showed no increase in thrombotic events, with the single exception of a signal for myocardial infarction with transdermal combined cyclic therapy, an estimate based on small numbers. This is observational and vulnerable to confounding by indication, but it is large, contemporary and consistent with the mechanistic expectation that the first-pass hepatic effect drives the risk, and it strengthens the case that route of administration matters more than the fact of treatment itself.

Staying with hormonal and metabolic disease, PLOS Medicine published a systematic review and meta-analysis by Olalere and colleagues on lifestyle interventions in polyendocrine metabolic ovarian syndrome, the condition previously known as polycystic ovary syndrome [2]. Thirty-four studies and just under nineteen hundred participants were pooled against minimal or usual care. Women in lifestyle programmes were roughly four times as likely to achieve regular menstrual cycles, and showed modest reductions in waist circumference, fasting glucose and fasting insulin. In subgroup analysis, dietary interventions did more for fasting glucose while exercise did more for waist circumference and insulin, and the benefits were largest in women who were overweight or obese, extending to testosterone and lipids. Heterogeneity between studies was high, which the authors flag as the principal limitation, and the menstrual regularity estimate rests on only five small trials. The evidence here supports existing international recommendations rather than overturning them, and it suggests diet and exercise are complementary rather than one being superior.

Turning to benign gynaecologic and obstetric procedures, two papers in Obstetrics and Gynecology tested interventions where the honest answer is nuanced. Allen and colleagues report the ULTRA study, a multicentre prospective cohort of just over four hundred premenopausal women with symptomatic fibroids treated by either laparoscopic radiofrequency ablation or myomectomy, followed with validated symptom and quality-of-life instruments for up to two years [3]. Just over half of participants identified as Black, which matters for generalisability in fibroid research. Both treatments produced large and sustained improvements. In propensity-weighted models myomectomy showed slightly greater gains in symptom severity and quality of life, but the differences, around five and six points respectively, sit well below the thresholds considered minimally clinically important, and the modest early advantages in functional domains had faded by twenty-four months. This is a cohort, not a randomised trial, so selection effects are handled statistically rather than by design, but it supports counselling that presents ablation as delivering broadly comparable symptom relief over two years.

Also in Obstetrics and Gynecology, Soffer and colleagues randomised more than twelve hundred nulliparous patients with singleton term pregnancies to hip extension at the moment of crowning, meaning lowering the legs out of the usual flexed position, versus usual care [4]. The primary composite of second, third or fourth degree lacerations was not significantly different between groups, at about two thirds of deliveries in each arm. So the trial is negative on its primary outcome. A quarter of those assigned to the intervention did not receive it, and in unadjusted as-treated analyses extension was associated with fewer significant lacerations and fewer obstetric anal sphincter injuries, about five percent versus ten percent, but those differences lost significance after adjustment. An ordinal analysis did show a protective shift toward more intact perineums. The authors conclude plainly that hip extension did not reduce significant lacerations; the as-treated signal is hypothesis-generating at best, given non-adherence is not random.

Gynaecologic oncology supplied four papers, all in Gynecologic Oncology, and two of them concern vulvar cancer. Mörsky and colleagues used Finnish national registry data to compare all primary vulvar squamous cell carcinoma surgeries from a radical-surgery era in the early 2000s with a personalised-surgery era in the mid-2010s, roughly three hundred and three hundred and sixty patients respectively [5]. Two-year overall survival rose about ten points, to around seventy-seven percent, and after adjusting for comorbidity and adjuvant treatment the personalised era was associated with roughly sixty percent lower all-cause and disease-specific mortality. The trade-off was more postoperative complications, about twenty percent versus eight percent, and a near doubling of reoperations, without delays to adjuvant treatment. These are non-contemporaneous cohorts, so improvements in imaging, pathology and adjuvant targeting are entangled with the surgical change, but the direction is reassuring for de-escalated, reconstruction-supported surgery. Complementing that, Frøding and colleagues prospectively enrolled 113 patients with early-stage vulvar cancer undergoing sentinel node biopsy with a hybrid tracer combining indocyanine green with technetium-labelled nanocolloid [6]. Sentinel nodes were found intraoperatively in ninety-two percent of groins and in nearly every patient, with fluorescence alone identifying nodes in about one in nine groins, mostly midline tumours, that preoperative imaging had missed. Nodal metastases were present in just under a quarter of patients, and after a median follow-up of just over four years isolated groin recurrence occurred in about two percent of node-negative groins. This is a single-arm feasibility series without a comparator, but the oncologic safety signal is encouraging.

Two further oncology papers look forward rather than settling anything. Salinaro and colleagues examined HER2 scoring in twenty-nine patients with high-grade endometrial cancer who had both an endometrial sampling and a hysterectomy specimen scored using gastric criteria [7]. Scores agreed in only about half of patients, and among the discordant cases most would have changed eligibility for HER2-directed therapy under current guidelines. Agreement with an external commercial laboratory's scores was worse still, and only about one in seven tumours carried ERBB2 amplification. The series is small and single-institution, but it raises a real question about whether a single specimen is sufficient to determine HER2 status. And Edwards and colleagues describe the design of a phase two, open-label trial enrolling forty patients with stage three or four epithelial ovarian cancer, combining carboplatin, paclitaxel and pembrolizumab around interval debulking, with hyperthermic intraperitoneal cisplatin in the first ten eligible patients and two years of maintenance pembrolizumab, plus olaparib for those with BRCA mutations or homologous recombination deficiency [8]. No results yet — this is a trial in progress, and worth knowing about only as a signal of where upfront ovarian cancer strategy is being tested.

Finally, two papers on prediction and diagnosis. In BJOG, Jarrett and colleagues analysed more than thirty thousand first pregnancies among First Nations women in Queensland over two decades, of which eighty-nine percent ended at term, and built an internally validated antenatal scoring rule for the probability of term birth [9]. Alongside expected predictors such as singleton pregnancy and the absence of chorioamnionitis or abruption, term birth was associated with attending five or more antenatal visits, metropolitan residence and higher socioeconomic status. The model is internally validated only and has not been tested prospectively, but the authors argue many predictors are amenable to culturally safe antenatal support. And in Ultrasound in Obstetrics and Gynecology, Berg and colleagues compared nineteen first-trimester abdominal ectopic pregnancies against fifty-seven tubal controls across four centres [10]. Abdominal implantation was around five times more likely after in vitro fertilisation and much less likely to present with vaginal bleeding, meaning the usual warning sign is often absent. Roughly a quarter of surgical cases had blood loss of five hundred millilitres or more, and four patients required transfusion compared with none in the tubal group. The authors propose four ultrasound criteria: a sac or trophoblast separate from uterus and ovaries, absence of a surrounding hypoechogenic tissue layer, a negative sliding organs sign, and trophoblastic flow arising from the peritoneum on colour Doppler. The numbers are small and retrospective, but the criteria are concrete.

If you only have time for one paper this week, make it the BMJ nationwide study of menopausal hormone therapy and thrombotic disease [1]. It is the largest contemporary dataset separating oral from transdermal preparations by dose and duration, and it reframes the risk conversation around route and regimen rather than around hormone therapy as a single category.

Here is what this week's evidence adds up to. Observational data now point strongly to oral oestrogen carrying a measurable but small absolute excess of venous and arterial thrombosis that rises with dose and duration, while transdermal routes appear neutral — firm enough to inform counselling, not a randomised finding. In benign gynaecology, two-year cohort data suggest radiofrequency ablation and myomectomy produce symptom relief that differs by less than patients can perceive, while a well-powered randomised trial found that hip extension at crowning did not reduce significant perineal lacerations, whatever the as-treated analyses hint. In vulvar cancer, national data and a prospective tracer series both support the personalised surgical approach, with the caveat of more complications and reoperations. And the HER2 concordance work in endometrial cancer, though small, unsettles the assumption that one specimen defines biomarker eligibility.

That's your roundup for This Week in Obstetrics and Gynecology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And think of one colleague — in any specialty — who never has time to keep up with the literature. Tell them about AudioScholar: a free ten-minute weekly for every specialty, to listen to in any podcast app, or to read at audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.